| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 41899 |
Unlisted procedure, dentoalveolar structures |
1,446 |
1,379 |
$5.35M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
7,765 |
6,983 |
$370K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,480 |
1,450 |
$83K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,449 |
574 |
$41K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
869 |
840 |
$33K |
| 20610 |
|
29 |
12 |
$6K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
93 |
93 |
$6K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
517 |
237 |
$4K |
| 97116 |
|
419 |
143 |
$3K |
| 76000 |
|
88 |
86 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
210 |
206 |
$746.58 |
| 62370 |
|
14 |
14 |
$237.80 |
| 97542 |
|
54 |
40 |
$44.09 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
72 |
54 |
$15.07 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
31 |
28 |
$1.04 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
270 |
249 |
$0.15 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
235 |
226 |
$0.13 |
| 80306 |
|
49 |
48 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
19 |
16 |
$0.00 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
176 |
53 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
22 |
17 |
$0.00 |
| 97166 |
|
14 |
14 |
$0.00 |